Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 patients. by Florena, A. et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Original Paper 
 Pathobiology 2007;74:317–322 
 DOI: 10.1159/000110024 
 Associations between Notch-2, Akt-1 and
HER2/neu Expression in Invasive Human Breast 
Cancer: A Tissue Microarray Immunophenotypic 
Analysis on 98 Patients 
 Ada Maria Florena    Claudio Tripodo    Carla Guarnotta    Sabrina Ingrao    
Rossana Porcasi    Anna Martorana    Giosuè Lo Bosco    Daniela Cabibi    
Vito Franco  
 Dipartimento di Patologia Umana, Università degli Studi di Palermo,  Palermo , Italia
 
Akt-1 expression, better degree of differentiation, and no 
lymph node involvement, along with the presence of HER2-
positive tumors with strong Notch-2 expression, support the 
role of Notch and Akt in breast cancer progression and sug-
gest that they may also represent new appealing therapeu-
tic targets.  Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 Breast cancer is the most common cancer in women, 
accounting for about one third of all cancers. As for most 
epithelial malignancies, the incidence of breast cancer 
shows a straight-line increase with every year of life, with 
the chance of developing breast cancer of about 1.4% in the 
5th decade rising to 3.6 after the age of 60 years  [1] . In ad-
dition to ageing, a number of breast cancer-predisposing 
factors have been described so far. Among these factors, a 
few, such as hormones, fared better in assessing risk and 
prognosis and eventually proved to be good substrates for 
the development of targeted therapies. As breast cancer is 
a hormone-dependent disease, the role of estrogens in tu-
mor initiation and promotion has been extensively inves-
tigated, highlighting the importance of the receptor status 
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 Abstract 
 Objective: We aimed to investigate the existence of associa-
tions between well-established and newly recognized bio-
logical and phenotypic features of breast cancer involved in 
tumor progression and prognosis.  Methods: Ninety-eight 
cases of invasive breast cancer were assessed for the immu-
nohistochemical expression of estrogen and progesterone 
receptors, Ki-67, HER2, Akt-1, and Notch-2, using the tissue 
microarray technique. Data regarding tumor histotype, his-
tological grade, tumor size and lymph node status were col-
lected for each patient and included in the analysis.  Results: 
Several significant associations between histological and/or 
immunophenotypic features came from the analysis of our 
data. Positive associations were observed between estrogen 
and progesterone receptors, tumor grade and proliferation 
index, tumor grade and HER2, Akt-1 and estrogen receptors, 
and Notch-2 and HER2. Inverse associations were noted be-
tween hormone receptors and tumor grade, hormone re-
ceptors and HER2, Akt-1 and tumor grade, and Akt-1 and 
nodal invasion.  Conclusions: Our results, showing the exis-
tence of a number of estrogen receptor-positive tumors with 
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of breast cancer cells and introducing successful therapies 
such as tamoxifen and aromatase inhibitors  [2] .
 Recently, the identification of a noticeable frequency 
of selected oncogene amplifications, namely HER2/neu, 
C-MYC, CCND1, has drawn much attention to the regu-
lation and cross talk of complex signaling pathways in 
human breast cancer  [2] . An ever-increasing number of 
molecules are being investigated, which play key roles in 
cell survival and differentiation and that are shared be-
tween multiple signaling pathways. Among them, Akt 
and its functional neighbors act on stimulation of growth 
and proliferation, inhibition of cell death, or, most often, 
a combination of these mechanisms  [3] .
 Notch proteins modulate differentiation, prolifera-
tion, and apoptotic programs and the demonstration that 
several human diseases result from mutations in genes 
encoding Notch receptors or their ligands has validated 
the Notch signaling pathway as a potential therapeutic 
target  [4] .
 The recent development of an array-based technique 
(tissue microarray, TMA) has provided the opportunity 
to investigate hundreds of molecular markers in the same 
set of specimens  [5, 6] . This technique allows a maximi-
zation of tissue resources and makes possible large scale 
retrospective studies using formalin-fixed, paraffin-em-
bedded small-core biopsies placed in the same block. 
 In the present study we aimed to investigate an explor-
atory hypothesis dealing with the possible associations 
between multiple biological features that can be involved 
in breast cancer progression and prognosis, by the histo-
logical and immunophenotypic analysis of 98 cases of 
human breast cancer using TMA.
 Methods 
 Tissue Samples and Microarrays 
 Between January 2003 and February 2004, 98 consecutive cases 
of invasive breast cancer were selected for review from the archives 
of the Institute of Pathology of the University of Palermo. Tissue 
samples had been fixed in 4% buffered formaldehyde (pH 7.0) and 
paraffin embedded. Lymph node samples (47 axillary dissectomies 
and 38 sentinel biopsies) were available in 85 out of 98 cases; in 13 
cases information on lymph node status was missing. Patients’ clin-
ical history and tumor characteristics including tumor histotype, 
histological grade, tumor size and lymph node status were collect-
ed from archival data. All the diagnoses had originally been based 
on the analysis of hematoxylin-eosin (HE)-stained slides followed 
by immunohistochemical evaluation. As far as neuroendocrine 
carcinoma was concerned the diagnosis was made on the ground 
of suggestive morphology along with immunophenotypic positiv-
ity to chromogranin, synaptophysin and NSE. Tumor grading had 
been assessed using the Scarff-Bloom-Richardson grading system 
modified by Elston and Ellis [7]. A histopathological reevaluation 
was performed to confirm the tumor histotype and grading as well 
as the neoplastic infiltration of lymph nodes. On reevaluation, the 
most representative areas of the tumors were identified on HE-
stained sections in order to produce a breast cancer TMA. Two 
cylinders of tissue, 0.6 mm in diameter, were removed from each of 
the 98 paraffin-embedded samples and placed into a single recipi-
ent block. This allowed for the simultaneous immunopheotypic 
analysis of the 98 cases on a single slide.
 Immunophenotypic Evaluation 
 Immunohistochemistry was performed on TMA slides to 
study the expression of a number of biological markers that are 
involved in tumor progression or that play a role in the assessment 
of prognosis. For this purpose the following primary antibodies 
were selected: estrogen receptor (MAb 1D5, BioGenex, dilution
1: 20); progesterone receptor (MAb 1A6, BioGenex, dilution 1: 20); 
Ki-67 (MAb MIB-1, DakoCytomation, dilution 1: 80); HER2 (Her-
cep test, DakoCytomation); Akt-1 (MAb 2H10, Cell Signaling, di-
lution 1: 50), and Notch-2 (MAb 25-255, Santa Cruz Biotechnology, 
dilution 1: 100). Immunostainings were carried out by means of the 
streptavidin-biotin complex method using a panel of antibodies 
effective on formalin-fixed, paraffin-embedded sections. The 
slides were microwave treated in 10 m M Tris/EDTA buffer, pH 9 
(Target Retrieval Solution, pH 9, 10 ! , DakoCytomation), for a to-
tal of 20 min for antigen unmasking. Endogenous peroxidase ac-
tivity was blocked by incubation for 10 min with 3% H 2 O 2 . Sec-
tions were subsequently incubated in the presence of a primary 
antibody overnight at 4 ° C. Normal mouse serum was used instead 
of primary antibodies as a negative control. The specimens were 
then incubated with biotinylated link antibody and peroxidase-
labeled streptavidin (Universal DakoCytomation LSAB + System-
HRP). Staining was completed by incubation with AEC (3-amino-
9-ethylcarbazole) substrate-chromogen (DakoCytomation AEC 
Substrate Chromogen Ready-to-Use). An immunophenotypic 
evaluation was performed independently by two of the authors 
(V.F., A.M.F.). Estrogen and progesterone receptor expression was 
reported by a dichotomous variable (0.1) and, owing to their high 
intratumoral variability, an average of  6 10% reactive neoplastic 
cells was considered as a positive reaction. HER2 was graded ac-
cording to the Dako scoring system . Akt-1 and Notch-2 expres-
sions were scored in a semiquantitative fashion (–, +, ++, +++) 
depending on the staining intensity and the percentage of the pos-
itive cells. The proliferation index was assessed by counting the 
number of Ki-67-positive cells per high-power microscopic field 
(400 ! ; 0.5 mm diameter) and was expressed as a percentage. All 
the morphological and immunophenotypic evaluations were per-
formed under a Nikon Eclipse 80i optical microscope.
 Statistical Analysis 
 In order to perform the statistical analysis, a set of 11 variables 
was considered which included pure categorical (tumor histotype, 
lymph node status, estrogen receptors, progesterone receptors), 
ordinal (histological grade, HER2, Akt-1, Notch-2), and continu-
ous variables (age on diagnosis, MIB-1 and primary tumor size). 
The continuous variables were scaled into ordinal categories ac-
cording to proper threshold values as follows: age:  ! 40,  6 40  ! 60, 
 6 60  ! 70,  6 70 years; tumor size:  ! 1,  6 1  ! 3,  6 3  ! 5,  6 5 cm;
Ki-67:  ! 10,  6 10  ! 40,  6 40%. A   2 test was performed for each pos-
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in a standard way when the variables were both pure categorical; 
otherwise, if there was at least one ordinal variable, only those 
groupings between the ordinal variable categories that were con-
sidered sound were included in the calculation. In this latter case 
we considered the variables as associated when at least one group-
ing that was sound showed a significant association, verifying also 
that in the contingency table 80% of the cells had expected frequen-
cies greater than 5 and that all the cells had expected frequencies 
greater than 1. Fifty-five single statistical tests were performed.
 This method allowed us to perform an in-depth study of the 
associations between the above-mentioned variables. A mini-
mum p value of 0.05 was considered to confirm associations with 
a probability of 95%  [8] . Due to the exploratory character of the 
study, no p value correction was done.
 Results 
 All the specimens collected for the study were from fe-
male patients aged 34–88 years (median age 66; minimum 
34, maximum 88). On histopathological revision all the 
98 diagnoses of invasive breast cancer were confirmed. 
All the histological data are detailed in  table 1 . The tu-
mors were divided according to their histotype as follows: 
65 infiltrating ductal carcinomas, 27 infiltrating lobular, 
2 tubular, 1 medullary, 1 papillary, 1 sarcomatoid, and 1 
gelatinous; 23 cases showed also a second histotype, 
namely infiltrating ductal cancer in 4 cases, infiltrating 
lobular cancer in 6, gelatinous cancer in 3, tubular cancer 
in 3, and neuroendocrine cancer in 7. Of these 23 cases, 
only the primary histotype was included in the TMA. 
Twenty-three cases were grade one, 54 were grade two, 
and 21 were grade three. Of the 85 cases in which lymph 
node samples were available, 39 showed the presence of 
metastatic colonization while 46 were not involved.
 The results of the immunophenotypic evaluation of 
TMA are reported in  table 2 . Overall, estrogen and pro-
gesterone receptors were both expressed in 63 tumors 
while estrogen receptors alone were expressed in 8 cases. 
A significant expression of HER2 (++, +++) was observed 
in 19 cases, 11 of which were scored ++ and 8 were scored 
+++. Akt-1 was expressed in 50 cases, its expression in 
malignant cells ranging from a mild (+) to strong (+++) 
cytoplasmic staining. Notch-2 proved to be expressed in 
a rather high percentage of breast cancers (67%) giving a 
cytoplasmic staining pattern; its positivity was consid-
ered significant (++, +++) only in 18 out of 98 cases.
 On statistical analysis several associations between 
histological and/or immunophenotypic parameters were 
found and the results are summarized in  table 3 .
 Significant positive associations were observed be-
tween estrogen and progesterone receptors, tumor grade 
Table 1. Frequencies and percentage of pathological features of 
the 98 cases (histological tumor types, tumor grades and lymph 
node metastasis)
Number












Grade 1 23 (23.5)
2 54 (55)
3 21 (21.4)
Lymph node positive 39 (40)
negative 46 (47)
not available 13
Figures in parentheses represent percentage.
Table 2. Results of the immunophenotypic evaluation on tissue 
microarray
Number
ER expression positive 71 (72.5)
negative 27 (27.5)
PR expression positive 63 (64.3)
negative 35 (34.7)
HER2 score –/+ 16 (16.3)
++ 11 (11.2)
+++ 8 (8.2)








Figures in parentheses represent percentage. ER = Estrogen 
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and proliferation index, and tumor grade and HER2. In-
verse associations were noted between hormone receptors 
and tumor grade, and hormone receptors and HER2.
 Akt-1 proved to be negatively associated with the tu-
mor grade, its expression being strong in well-differenti-
ated tumors and reduced in high-grade ones (p = 0.02, 
 fig. 1 a), while it showed a direct correlation with estrogen 
receptors. Akt-1 expression was also associated with the 
presence of nodal metastases in an inverse fashion (p = 
0.02). 
 Notch-2 showed a positive association with HER2
(p = 0.004,  fig. 1 b) although it showed no significant as-
sociation with tumor grade or hormone receptor status.
 Discussion 
 The study of Akt and Notch protein families, both in-
volved in the orchestration of intracellular signaling, has 
followed a rather unusual development in which func-
tional studies occurred prior to and overshadowed those 
regarding the expression of Notch and Akt proteins in 
neoplastic diseases. The activation of the Akt pathway has 
been reported to provide cells with a survival signal that 
allows them to withstand apoptotic stimuli. In breast can-
cer, Akt phosphorylation has been correlated with HER2 
overexpression and is considered an effector of HER2-in-
duced blockage of tamoxifen action by an active interplay 
between PI3K and Akt signaling and the estrogen recep-
tor  [9] . Aberrant Notch signaling has been observed in a 
number of human cancers suggesting a possible general 
role of Notch signaling in tumor formation by causing 
cells to adopt a proliferative cell fate  [10] . It has also been 
reported that unregulated Notch signaling prevents ter-
minal differentiation of mammary epithelial cells. Aber-
rant Notch signaling could keep cells in a proliferative 
state leading to duct dysplasia with an increased risk of 
progression to carcinoma  [10] . Recently, the identification 
of drugs such as   -secretase inhibitors  [11] and Ly900/
mTOR inhibitor rapamycin  [12, 13] able to interfere, re-
spectively, with Notch signaling and PI3/Akt-related path-
ways has drawn much interest to the opportunity to in-
vestigate their role as potential targets for new adjuvant 
therapies. In particular, the promising effects of therapies 
combining HER2 inhibitors (gefitinib) or tamoxifen and 
rapamycin have been recently published  [14, 15] .
 On this basis we studied the immunophenotypic ex-
pression of these two molecules along with that of well-
established breast cancer markers and analyzed the rela-
tive associations.
Table 3. Significant associations between the studied variables
Variable 1 Variable 2 Association p value 2
ER PR + 0.002 39.19
ER grade – 0.02 4.82
PR grade – 0.03 4.36
Grade MIB-1 + 0.008 5.53
ER HER2 – 0.02 4.33
HER2 grade + 0.005 6.02
HER2 MIB-1 + 0.01 7.41
Akt-1 ER + 0.02 3.89
Akt-1 grade – 0.04 4.20
Akt-1 HER2 – 0.03 6.67
Akt-1 LN – 0.02 4.23
Notch-2 HER2 + 0.004 4.08
ER = Estrogen receptors; PR = progesterone receptors; LN = 




 Fig. 1.  a Akt-1 (+++) is intensively expressed in a case of HER2-
negative infiltrating ductal carcinoma G1.  b Notch-2 (++) and 
HER2 (+++) expressions are nicely associated in this case of infil-
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 In order to obtain a thorough standardization, a large 
number of invasive breast cancers were evaluated by the 
TMA technique that allowed a homogeneous interpreta-
tion of the immunohistochemical results and the adop-
tion of a semiquantitative scoring system.
 TMA is a method of harvesting small disks of tissue 
from a range of standard histological sections and plac-
ing them in an array on a recipient paraffin block so as to 
analyze them simultaneously  [16] . As TMA analysis fa-
cilitates studies of the clinical significance of new genes 
discovered in genomic screenings of model systems, they 
have been extensively used to study gene targets. It is also 
possible to use this technique to associate molecular al-
terations with a specific stage of tumor progression  [17] .
 Some of the direct or inverse associations resulting 
from the analysis of our results, such as those between 
estrogen and progesterone receptors, tumor grade, HER2, 
and proliferation index, have already been reported in the 
literature and extensively studied  [2] . In a recent paper 
the association of estrogen receptor, progesterone recep-
tor, bcl-2, HER2/neu, p53 and Ki-67 with clinicopatho-
logic features and outcome in 103 patients, studied by 
means of TMA, showed that PR, Ki-67, tumor stage and 
nodal status were prognostic factors for distant failure in 
early-stage breast cancer in young patients  [18] . Besides 
these, new interesting associations also resulted from the 
statistical analysis of our data.
 The immunohistochemical evaluation of Akt-1 ex-
pression showed a positive association with estrogen re-
ceptor expression and an inverse association with tumor 
grade and nodal metastases, which is in favors of an in-
terpretation of Akt-1 function in estrogen-stimulated 
growth and cellular differentiation more than in tumor 
progression. Although these data could appear in con-
trast with the already reported coexpression of Akt-1 and 
HER2 in some cell lines, they are in keeping with the re-
sults of Stål et al.  [9] reporting a significant frequency of 
Akt-1 expression in estrogen receptor-positive tumors 
 [19] and with the moderate to high expression of phos-
phorylated Akt reported in  1 70% of invasive breast car-
cinoma in a series studied with the microarray technique 
 [20] . The activation of the Akt pathway has been found 
early in breast cancer, even in the in situ stage  [21] . More 
recently, aberrant Akt-1 signaling has already been re-
lated to the blockage of antiestrogen activity implying 
that steroid-receptor-positive cancers with high Akt-1 
signaling might be candidates for antiestrogens in com-
bination with Akt-1 inhibitors  [22, 23] .
 In our study the immunohistochemical expression of 
Notch-2 was significantly stronger in HER2-positive tu-
mors (++, +++) although no significant associations were 
found with tumor grade or hormone receptor status.
 Previous studies have already reported the expression 
of Notch family molecules in human breast cancers  [24, 
25] observing higher levels of expression in tumors than 
in normal breast tissue. The evaluation of Notch-1 and 
Notch-2 mRNA quantification showed that increased 
levels of Notch-1 receptor were associated with poorly 
differentiated tumors while Notch-2 was not significant-
ly related to tumor grade  [24] . In the family of Notch re-
ceptors, all of which are involved in different stages of 
tumor progression, Notch-2 acts as a transcriptional and 
functional regulator of Notch-1 and Notch-3  [26] . Along 
with other genes, Notch-2 has recently been identified in 
different tamoxifen-resistant clones  [20] . Given the in-
volvement of Notch-2 in cell cycle arrest and cell growth 
and the possible role of its disrupted form in rendering 
tumor cells tamoxifen resistant it follows that its immu-
nophenotypic expression can provide useful information 
about the possible involvement of Notch proteins in breast 
cancer dynamics.
 Although the lack of information regarding both a 
true quantitative analysis of Notch-2 and Akt-1 expres-
sion in our samples and the functional status of these two 
proteins does not permit us to speculate on the possible 
mechanisms underlining these relationships, we would 
like to stress the importance of reporting the association 
of such molecules with that of histological and pheno-
typic markers of tumor progression and prognosis. We 
noted the existence of a conspicuous number of estrogen 
receptor-positive tumors in which Akt-1 is coexpressed 
and that show a better degree of differentiation with no 
lymph node involvement along with the presence of a 
population of HER2-positive tumors with strong Notch-
2 expression. In these cases, properly designed studies 
evaluating the response to tamoxifen- and trastuzumab-
based therapies and focusing on the influence of Akt-1 
and Notch-2 are definitely needed.
 In conclusion, our results further support the role of 
molecules like Notch and Akt that, although not yet in-
cluded in treatment strategies for breast cancers, may 
represent new appealing therapeutic targets for conven-
tional therapy-resistant tumors.
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